The prevalence of healthcare-associated infections is currently a critical issue in the medical community, resulting in compromised patient healthcare and billions of dollars in corrective costs. Further complicating this issue is the emergence of multi-drug-resistant organisms.
Symbios has developed an advanced manufacturing platform, based on plasma chemistry, that is being applied to the synthesis of novel antimicrobial solutions in a collaborative effort with a bioscience partner. Lab testing of this approach has demonstrated excellent antimicrobial effects against a wide range of microbial contaminants and thus demonstrates great promise as an anti-infective healthcare product. The Symbios plasma technology using the newly designed Selective Plasma Oxidation Reactor™ (SPOR™) represents a significant advancement toward the production of anti-infective solutions due to its continuous flow configuration, low energy consumption, and faster reaction times.